Plasma concentrations of myeloperoxidase predict mortality after myocardial infarction.

[1]  S. Hazen,et al.  Plasma myeloperoxidase levels in patients with chronic heart failure. , 2006, The American journal of cardiology.

[2]  B. Pathik,et al.  Myeloperoxidase and C-reactive protein augment the specificity of B-type natriuretic peptide in community screening for systolic heart failure. , 2006, American heart journal.

[3]  V. Cameron,et al.  Angiotensin Type-1 Receptor A1166C Gene Polymorphism Correlates With Oxidative Stress Levels in Human Heart Failure , 2006, Hypertension.

[4]  H. Klemm,et al.  Heparins Increase Endothelial Nitric Oxide Bioavailability by Liberating Vessel-Immobilized Myeloperoxidase , 2006, Circulation.

[5]  R. Doughty,et al.  Comparison of B-type natriuretic peptides for assessment of cardiac function and prognosis in stable ischemic heart disease. , 2006, Journal of the American College of Cardiology.

[6]  J. Borawski.  Myeloperoxidase as a marker of hemodialysis biocompatibility and oxidative stress: the underestimated modifying effects of heparin. , 2006, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[7]  A. Kumar,et al.  Statins downregulate myeloperoxidase gene expression in macrophages. , 2005, Biochemical and biophysical research communications.

[8]  Stanley L Hazen,et al.  ATVB in Focus Redox Mechanisms in Blood Vessels , 2005 .

[9]  J. Stamler,et al.  NO/redox disequilibrium in the failing heart and cardiovascular system. , 2005, The Journal of clinical investigation.

[10]  J. Keaney,et al.  Role of oxidative modifications in atherosclerosis. , 2004, Physiological reviews.

[11]  T. Meinertz,et al.  Myeloperoxidase enhances nitric oxide catabolism during myocardial ischemia and reperfusion. , 2004, Free radical biology & medicine.

[12]  A. Chait,et al.  The myeloperoxidase product hypochlorous acid oxidizes HDL in the human artery wall and impairs ABCA1-dependent cholesterol transport. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[13]  Marlene Goormastic,et al.  Serum Myeloperoxidase Levels Independently Predict Endothelial Dysfunction in Humans , 2004, Circulation.

[14]  Michael Kinter,et al.  Apolipoprotein A-I is a selective target for myeloperoxidase-catalyzed oxidation and functional impairment in subjects with cardiovascular disease. , 2004, The Journal of clinical investigation.

[15]  J. Keaney,et al.  Reactive oxygen species-mediated signal transduction in the endothelium. , 2004, Endothelium : journal of endothelial cell research.

[16]  D. Tsikas,et al.  Urinary 8-iso-Prostaglandin F2&agr; as a Risk Marker in Patients With Coronary Heart Disease: A Matched Case-Control Study , 2004 .

[17]  H. Ishizaka,et al.  Matrix metalloproteinase; , 2022 .

[18]  G. FitzGerald,et al.  Oxidative stress and cardiovascular injury: Part II: animal and human studies. , 2003, Circulation.

[19]  E. Topol,et al.  Prognostic value of myeloperoxidase in patients with chest pain. , 2003, The New England journal of medicine.

[20]  G. FitzGerald,et al.  Oxidative Stress and Cardiovascular Injury: Part I: Basic Mechanisms and In Vivo Monitoring of ROS , 2003, Circulation.

[21]  C. Heeschen,et al.  Myeloperoxidase Serum Levels Predict Risk in Patients With Acute Coronary Syndromes , 2003, Circulation.

[22]  Eric J. Topol,et al.  Myeloperoxidase and Plasminogen Activator Inhibitor 1 Play a Central Role in Ventricular Remodeling after Myocardial Infarction , 2003, The Journal of experimental medicine.

[23]  A. Kettle,et al.  3-Chlorotyrosine as a Marker of Protein Damage by Myeloperoxidase in Tracheal Aspirates From Preterm Infants: Association With Adverse Respiratory Outcome , 2003, Pediatric Research.

[24]  Roberto Colombo,et al.  Protein carbonyl groups as biomarkers of oxidative stress. , 2003, Clinica chimica acta; international journal of clinical chemistry.

[25]  J. Heinecke.  Oxidative stress: new approaches to diagnosis and prognosis in atherosclerosis. , 2003, The American journal of cardiology.

[26]  J. Taguchi,et al.  Increased level of advanced oxidation protein products in patients with coronary artery disease. , 2002, Atherosclerosis.

[27]  R. Dean,et al.  Disease stage-dependent accumulation of lipid and protein oxidation products in human atherosclerosis. , 2002, The American journal of pathology.

[28]  K. Hashimura,et al.  Transcardiac 8-iso-prostaglandin F(2 alpha)generation from acute myocardial infarction heart: insight into abrupt reperfusion and oxidant stress. , 2001, Prostaglandins, leukotrienes, and essential fatty acids.

[29]  G. FitzGerald,et al.  Angioplasty increases coronary sinus F2-isoprostane formation: evidence for in vivo oxidative stress during PTCA. , 2001, Journal of the American College of Cardiology.

[30]  D. Harrison,et al.  Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress. , 2000, Circulation research.

[31]  A. Kettle,et al.  Biomarkers of myeloperoxidase-derived hypochlorous acid. , 2000, Free radical biology & medicine.

[32]  J G Turner,et al.  Neuroendocrine prediction of left ventricular function and heart failure after acute myocardial infarction , 1999, Heart.

[33]  C. Winterbourn,et al.  Protein carbonyl measurement by enzyme-linked immunosorbent assay. , 1999, Methods in enzymology.

[34]  C. Frampton,et al.  Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin: new neurohormonal predictors of left ventricular function and prognosis after myocardial infarction. , 1998, Circulation.

[35]  A. Richards,et al.  Adrenomedullin(1-52) measured in human plasma by radioimmunoassay: plasma concentration, adsorption, and storage. , 1998, Clinical chemistry.

[36]  R. Doughty,et al.  Immunoreactive amino‐terminal pro‐brain natriuretic peptide (NT‐PROBNP): a new marker of cardiac impairment , 1997, Clinical endocrinology.

[37]  S. L. Hazen,et al.  3-Chlorotyrosine, a specific marker of myeloperoxidase-catalyzed oxidation, is markedly elevated in low density lipoprotein isolated from human atherosclerotic intima. , 1997, The Journal of clinical investigation.

[38]  A. Kettle,et al.  Myeloperoxidase: a key regulator of neutrophil oxidant production. , 1997, Redox report : communications in free radical research.

[39]  A. Rebuzzi,et al.  Intracellular neutrophil myeloperoxidase is reduced in unstable angina and acute myocardial infarction, but its reduction is not related to ischemia. , 1996, Journal of the American College of Cardiology.

[40]  A. Daugherty,et al.  Myeloperoxidase, a catalyst for lipoprotein oxidation, is expressed in human atherosclerotic lesions. , 1994, The Journal of clinical investigation.